The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats

Charles Henley, James Davis, Gerald Miller, Edward Shatzen, Russ Cattley, Xiaodong Li, David Martin, Wei Yao, Nancy E Lane, Victoria Shalhoub

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Calcimimetics and vitamin D sterols reduce serum parathyroid hormone (PTH) in patients with secondary hyperparathyroidism receiving dialysis, a disease state associated with parathyroid hyperplasia, vascular calcification, bone disease, and increased mortality. The aim of this study was to determine the effects of the research calcimimetic AMG 641 (Amgen, Inc., Thousand Oaks, CA) or calcitriol (Sigma Aldrich Corporation, St. Louis, MO) on vascular calcification in a rodent model of progressive uremia with accompanying secondary hyperparathyroidism induced by dietary adenine. Treatment effects on parathyroid gland hyperplasia and bone loss were also investigated. Rats were treated daily with vehicle, calcitriol (10 ng), AMG 641 (3 mg/kg), or no treatment during the 4 week period the animals were fed adenine. The uremia-induced increases in serum PTH levels were significantly attenuated by both AMG 641 (> 90%) and calcitriol (~ 50%). AMG 641 significantly reduced calcium-phosphorus product (Ca × P) and significantly attenuated the development of both parathyroid hyperplasia and vascular calcification. In addition, AMG 641 prevented the defects in trabecular bone volume, trabecular number, and bone mineralization, as well as increases in trabecular spacing in this rodent model of secondary hyperparathyroidism. Calcitriol (10 ng/rat) decreased osteoid surface/bone surface, but had no effects on other bone parameters, or parathyroid hyperplasia (likely due to the lower PTH suppressive effect of calcitriol at the dose used in this study). However, this dose of calcitriol significantly exacerbated vascular calcification. These results suggest that calcimimetics can reduce the development of vascular calcification, parathyroid hyperplasia and bone abnormalities associated with secondary hyperparathyroidism.

Original languageEnglish (US)
Pages (from-to)306-313
Number of pages8
JournalEuropean Journal of Pharmacology
Volume616
Issue number1-3
DOIs
StatePublished - Aug 15 2009

Fingerprint

Vascular Calcification
Calcitriol
Hyperplasia
Secondary Hyperparathyroidism
Bone and Bones
Parathyroid Hormone
Uremia
Adenine
Rodentia
Physiologic Calcification
Parathyroid Glands
Bone Diseases
Sterols
Serum
Vitamin D
Phosphorus
N-((6-(methyloxy)-4'-(trifluoromethyl)-3-biphenylyl)methyl)-1-phenylethanamine
Dialysis
Calcium
Mortality

Keywords

  • Bone
  • Calcimimetic
  • Calcium-sensing receptor
  • Parathyroid gland hyperplasia
  • Secondary hyperparathyroidism
  • Vascular calcification
  • Vitamin D sterol

ASJC Scopus subject areas

  • Pharmacology

Cite this

The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats. / Henley, Charles; Davis, James; Miller, Gerald; Shatzen, Edward; Cattley, Russ; Li, Xiaodong; Martin, David; Yao, Wei; Lane, Nancy E; Shalhoub, Victoria.

In: European Journal of Pharmacology, Vol. 616, No. 1-3, 15.08.2009, p. 306-313.

Research output: Contribution to journalArticle

Henley, Charles ; Davis, James ; Miller, Gerald ; Shatzen, Edward ; Cattley, Russ ; Li, Xiaodong ; Martin, David ; Yao, Wei ; Lane, Nancy E ; Shalhoub, Victoria. / The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats. In: European Journal of Pharmacology. 2009 ; Vol. 616, No. 1-3. pp. 306-313.
@article{1fcb7c8d220f44d2ad81be49fb198f63,
title = "The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats",
abstract = "Calcimimetics and vitamin D sterols reduce serum parathyroid hormone (PTH) in patients with secondary hyperparathyroidism receiving dialysis, a disease state associated with parathyroid hyperplasia, vascular calcification, bone disease, and increased mortality. The aim of this study was to determine the effects of the research calcimimetic AMG 641 (Amgen, Inc., Thousand Oaks, CA) or calcitriol (Sigma Aldrich Corporation, St. Louis, MO) on vascular calcification in a rodent model of progressive uremia with accompanying secondary hyperparathyroidism induced by dietary adenine. Treatment effects on parathyroid gland hyperplasia and bone loss were also investigated. Rats were treated daily with vehicle, calcitriol (10 ng), AMG 641 (3 mg/kg), or no treatment during the 4 week period the animals were fed adenine. The uremia-induced increases in serum PTH levels were significantly attenuated by both AMG 641 (> 90{\%}) and calcitriol (~ 50{\%}). AMG 641 significantly reduced calcium-phosphorus product (Ca × P) and significantly attenuated the development of both parathyroid hyperplasia and vascular calcification. In addition, AMG 641 prevented the defects in trabecular bone volume, trabecular number, and bone mineralization, as well as increases in trabecular spacing in this rodent model of secondary hyperparathyroidism. Calcitriol (10 ng/rat) decreased osteoid surface/bone surface, but had no effects on other bone parameters, or parathyroid hyperplasia (likely due to the lower PTH suppressive effect of calcitriol at the dose used in this study). However, this dose of calcitriol significantly exacerbated vascular calcification. These results suggest that calcimimetics can reduce the development of vascular calcification, parathyroid hyperplasia and bone abnormalities associated with secondary hyperparathyroidism.",
keywords = "Bone, Calcimimetic, Calcium-sensing receptor, Parathyroid gland hyperplasia, Secondary hyperparathyroidism, Vascular calcification, Vitamin D sterol",
author = "Charles Henley and James Davis and Gerald Miller and Edward Shatzen and Russ Cattley and Xiaodong Li and David Martin and Wei Yao and Lane, {Nancy E} and Victoria Shalhoub",
year = "2009",
month = "8",
day = "15",
doi = "10.1016/j.ejphar.2009.05.013",
language = "English (US)",
volume = "616",
pages = "306--313",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats

AU - Henley, Charles

AU - Davis, James

AU - Miller, Gerald

AU - Shatzen, Edward

AU - Cattley, Russ

AU - Li, Xiaodong

AU - Martin, David

AU - Yao, Wei

AU - Lane, Nancy E

AU - Shalhoub, Victoria

PY - 2009/8/15

Y1 - 2009/8/15

N2 - Calcimimetics and vitamin D sterols reduce serum parathyroid hormone (PTH) in patients with secondary hyperparathyroidism receiving dialysis, a disease state associated with parathyroid hyperplasia, vascular calcification, bone disease, and increased mortality. The aim of this study was to determine the effects of the research calcimimetic AMG 641 (Amgen, Inc., Thousand Oaks, CA) or calcitriol (Sigma Aldrich Corporation, St. Louis, MO) on vascular calcification in a rodent model of progressive uremia with accompanying secondary hyperparathyroidism induced by dietary adenine. Treatment effects on parathyroid gland hyperplasia and bone loss were also investigated. Rats were treated daily with vehicle, calcitriol (10 ng), AMG 641 (3 mg/kg), or no treatment during the 4 week period the animals were fed adenine. The uremia-induced increases in serum PTH levels were significantly attenuated by both AMG 641 (> 90%) and calcitriol (~ 50%). AMG 641 significantly reduced calcium-phosphorus product (Ca × P) and significantly attenuated the development of both parathyroid hyperplasia and vascular calcification. In addition, AMG 641 prevented the defects in trabecular bone volume, trabecular number, and bone mineralization, as well as increases in trabecular spacing in this rodent model of secondary hyperparathyroidism. Calcitriol (10 ng/rat) decreased osteoid surface/bone surface, but had no effects on other bone parameters, or parathyroid hyperplasia (likely due to the lower PTH suppressive effect of calcitriol at the dose used in this study). However, this dose of calcitriol significantly exacerbated vascular calcification. These results suggest that calcimimetics can reduce the development of vascular calcification, parathyroid hyperplasia and bone abnormalities associated with secondary hyperparathyroidism.

AB - Calcimimetics and vitamin D sterols reduce serum parathyroid hormone (PTH) in patients with secondary hyperparathyroidism receiving dialysis, a disease state associated with parathyroid hyperplasia, vascular calcification, bone disease, and increased mortality. The aim of this study was to determine the effects of the research calcimimetic AMG 641 (Amgen, Inc., Thousand Oaks, CA) or calcitriol (Sigma Aldrich Corporation, St. Louis, MO) on vascular calcification in a rodent model of progressive uremia with accompanying secondary hyperparathyroidism induced by dietary adenine. Treatment effects on parathyroid gland hyperplasia and bone loss were also investigated. Rats were treated daily with vehicle, calcitriol (10 ng), AMG 641 (3 mg/kg), or no treatment during the 4 week period the animals were fed adenine. The uremia-induced increases in serum PTH levels were significantly attenuated by both AMG 641 (> 90%) and calcitriol (~ 50%). AMG 641 significantly reduced calcium-phosphorus product (Ca × P) and significantly attenuated the development of both parathyroid hyperplasia and vascular calcification. In addition, AMG 641 prevented the defects in trabecular bone volume, trabecular number, and bone mineralization, as well as increases in trabecular spacing in this rodent model of secondary hyperparathyroidism. Calcitriol (10 ng/rat) decreased osteoid surface/bone surface, but had no effects on other bone parameters, or parathyroid hyperplasia (likely due to the lower PTH suppressive effect of calcitriol at the dose used in this study). However, this dose of calcitriol significantly exacerbated vascular calcification. These results suggest that calcimimetics can reduce the development of vascular calcification, parathyroid hyperplasia and bone abnormalities associated with secondary hyperparathyroidism.

KW - Bone

KW - Calcimimetic

KW - Calcium-sensing receptor

KW - Parathyroid gland hyperplasia

KW - Secondary hyperparathyroidism

KW - Vascular calcification

KW - Vitamin D sterol

UR - http://www.scopus.com/inward/record.url?scp=67651087160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651087160&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2009.05.013

DO - 10.1016/j.ejphar.2009.05.013

M3 - Article

C2 - 19470383

AN - SCOPUS:67651087160

VL - 616

SP - 306

EP - 313

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -